Cost of Revenue Trends: Teva Pharmaceutical Industries Limited vs Ionis Pharmaceuticals, Inc.

Teva vs. Ionis: Diverging Cost of Revenue Paths

__timestampIonis Pharmaceuticals, Inc.Teva Pharmaceutical Industries Limited
Wednesday, January 1, 20142417510009216000000
Thursday, January 1, 20153222920008296000000
Friday, January 1, 201634432000010044000000
Sunday, January 1, 201737464400011560000000
Monday, January 1, 2018182000010558000000
Tuesday, January 1, 201940000009351000000
Wednesday, January 1, 2020120000008933000000
Friday, January 1, 2021110000008284000000
Saturday, January 1, 2022140000007952000000
Sunday, January 1, 202391330008200000000
Monday, January 1, 2024112150008480000000
Loading chart...

Unveiling the hidden dimensions of data

Cost of Revenue Trends: A Tale of Two Pharmaceutical Giants

In the ever-evolving pharmaceutical industry, understanding cost dynamics is crucial. Teva Pharmaceutical Industries Limited and Ionis Pharmaceuticals, Inc. have shown contrasting trends in their cost of revenue from 2014 to 2023. Teva, a global leader, saw its cost of revenue peak in 2017 at approximately $11.56 billion, before gradually declining to around $8.2 billion by 2023. This represents a 29% decrease over six years, reflecting strategic cost management and market adjustments.

Conversely, Ionis Pharmaceuticals, a pioneer in RNA-targeted therapeutics, experienced a more volatile trajectory. Starting at $241 million in 2014, their costs surged to $374 million by 2017, only to plummet to $9 million in 2023. This dramatic 97% reduction highlights Ionis's shift towards more efficient operations and possibly a strategic pivot in their business model. These trends underscore the dynamic nature of the pharmaceutical sector, where adaptability is key.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025